PepLabo Download

Victoza® and heartburn

Indigestion on Victoza: 4–7% against 1% on placebo, reflux and gastritis common in Europe, cohort data on reflux and chest pain that is not heartburn.

Published · Updated · Victoza®: side effects by symptom · Written by the PepLabo editorial team

When to get help
Context and scope

Heartburn, indigestion and reflux are often used as one word, but the Victoza® documents count them separately. The US label measures dyspepsia, Europe adds reflux and gastritis, and Canada lists burping among common effects. This page sorts those terms for this once-daily liraglutide injection for type 2 diabetes, adds what population studies say about reflux on GLP-1 medicines, covers the other causes of a burning chest and sets out what helps and when it is not heartburn at all.

Key takeaways 5
  • Dyspepsia appears in US Table 1 at 4% on 1.2 mg and 7% on 1.8 mg, against 1% on placebo. [1]
  • The EU table puts dyspepsia, gastritis and gastro-oesophageal reflux disease in its common class, between 1 in 100 and 1 in 10 people. [2]
  • Canadian patient information lists burping, indigestion, gastritis and reflux among common side effects of Victoza®. [3]
  • In 24,708 UK adults starting GLP-1 medicines, reflux was 27% more likely over three years than in people starting SGLT-2 inhibitors. [4]
  • Victoza® slows stomach emptying, and the label asks you to tell your care team before surgery or deep sedation. [1]

Three words, three rows

Dyspepsia means discomfort in the upper belly, often with burning or early fullness after eating. MedlinePlus is clear that it is not the same as heartburn, which is a burning feeling behind the breastbone that usually comes from acid rising into the food pipe. [7][6] The Victoza® US label counts dyspepsia in Table 1, and the Medication Guide calls it indigestion. [1] The European table lists dyspepsia, gastritis and reflux disease as separate common reactions, and the leaflet explains that the sign of reflux is heartburn. [2]

Dyspepsia in the Victoza® adult placebo-controlled pool (US label, section 6.1, Table 1)
GroupPeople in groupReported dyspepsia
Placebo6611%
Liraglutide 1.2 mg6454%
Liraglutide 1.8 mg1,0247%

Indigestion, gastritis and reflux by trial

The Canadian monograph breaks the upper-gut complaints into separate rows for each trial. [3] Dyspepsia is the largest of them and shows the clearest rise at 1.8 mg; reflux itself was recorded in under 3% of people on Victoza® in every trial. [3]

Upper digestive events in Victoza® trials (Health Canada monograph, section 8.2, Tables 1–3; EU SmPC section 4.8)
Trial and termVictoza®Comparison
LEAD-2, dyspepsia [3]0.6 mg 3.7%; 1.2 mg 2.1%; 1.8 mg 7.0%Placebo 0.8%; glimepiride 1.2%
LEAD-2, gastritis [3]0.6 mg 3.3%; 1.2 mg 2.5%; 1.8 mg 5.0%Placebo 0.8%; glimepiride 0.8%
LEAD-2, reflux disease [3]0.6 mg 1.7%; 1.2 mg 0.8%; 1.8 mg 0.4%Placebo 0.0%; glimepiride 0.0%
LEAD-5, dyspepsia [3]1.8 mg 6.5%Placebo 0.9%; insulin glargine 1.7%
Trial 1860, dyspepsia [3]1.2 mg 3.2%; 1.8 mg 6.4%Sitagliptin 2.3%
Trial 1860, reflux disease [3]1.2 mg 1.4%; 1.8 mg 2.3%Sitagliptin 0.9%
EU frequency class [2]Dyspepsia, gastritis, reflux disease: common—

What studies outside the label add

Two recent analyses looked at reflux across GLP-1 medicines, not Victoza® alone. A UK cohort study emulating a trial followed 24,708 adults with type 2 diabetes who started a GLP-1 medicine and 89,096 who started an SGLT-2 inhibitor. Over about three years, reflux was 27% more likely with GLP-1 medicines, an extra 0.7 cases per 100 people, and its complications were also more frequent. [4] The authors note that diet and lifestyle were not recorded, so some confounding may remain. [4]

A 2025 meta-analysis of 55 placebo-controlled randomised trials judged that GLP-1 medicines probably increase reflux, by about 4 extra cases per 1,000 people, while having little or no effect on gastritis, oesophagitis and ulcers. [5] Neither study reports liraglutide separately, so they describe the class.

Why it might happen

Label-supported: Victoza® delays gastric emptying, which is part of how it lowers blood sugar after meals. [1] Food staying longer in the stomach is the documented change most closely tied to fullness and upper-belly discomfort.

Proposed in research: the cohort study names delayed stomach emptying as a known risk factor for reflux and tested whether GLP-1 medicines raise reflux risk; it found an association, which does not by itself prove the mechanism. [4]

General medicine: MedlinePlus explains heartburn as stomach contents moving back up when the muscle band at the bottom of the food pipe does not close tightly. [6]

Before surgery, sedation and other tablets

Because the stomach empties more slowly, rare cases of food or liquid entering the lungs have been reported in people on GLP-1 medicines who had general anaesthesia or deep sedation despite fasting as instructed. [1] The label says there is not enough data to recommend a specific way to reduce this risk and asks you to tell your healthcare providers about Victoza® before any planned procedure. [1] The European text says the higher chance of food remaining in the stomach should be considered before such procedures. [2]

The same slowing can, in principle, change how tablets taken by mouth are absorbed. In the label’s studies this did not reach a clinically relevant degree, but the label still asks for caution. [1]

Other causes of a burning chest

MedlinePlus lists a hiatal hernia, pregnancy and a range of medicines that can cause or worsen heartburn, including beta-blockers and calcium channel blockers for blood pressure or heart disease, some asthma medicines, sedatives and tricyclic antidepressants. [6] For indigestion it adds gallstones, gastritis, pancreatitis, ulcers, and aspirin or anti-inflammatory painkillers, along with eating too fast, fatty meals, alcohol and stress. [7] Victoza®’s own warnings include pancreatitis and gallbladder disease, both of which can start as upper-belly discomfort. [1]

Most importantly, MedlinePlus warns that some people who think they have heartburn are having a heart attack. [6] Many Victoza® users have type 2 diabetes with heart disease, which is the group studied in the LEADER trial. [1]

What the sources describe

  • Trigger foods and drinks: MedlinePlus lists alcohol, caffeine, fizzy drinks, chocolate, citrus, mint, spicy or fatty food and tomato sauces as common reflux triggers. [6]
  • Eating habits: smaller meals, not bending or exercising right after eating, and leaving a gap between the last meal and bedtime. [6]
  • At night: raising the head of the bed helps more than extra pillows, according to MedlinePlus. [6]
  • Other habits: loose clothing around the waist, stopping smoking and ways to manage stress. [6]
  • Over-the-counter medicines: MedlinePlus describes antacids and acid-reducing products; ask your pharmacist which fits with your other medicines, and do not stop a prescribed medicine on your own. [6]

Victoza® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk A/S.

When to get help

The signs and contact information below come from this article’s sourced guidance.

Emergency

  • Burning with squeezing, crushing or pressure in the chest, or pain spreading to the jaw, arm or back with sweating

    Contact: Emergency services (911 or local number)

    MedlinePlus [6][7]

  • Vomit with blood or coffee-ground material, or black or maroon stools

    Contact: Urgent medical care

    MedlinePlus [6]

  • Severe upper belly pain that does not go away, sometimes into the back

    Contact: Stop Victoza® and call your provider straight away

    Medication Guide [1]

Today

  • Upper belly pain with yellow skin or eyes, fever or clay-coloured stools

    Contact: Your provider, the same day

    Medication Guide [1]

  • Trouble swallowing, weight loss you were not trying for, or a cough that will not go away

    Contact: Contact your provider

    MedlinePlus [6]

At your next appointment

  • Heartburn several times a week, or not settling after a few weeks of self-care

    Contact: Book an appointment

    MedlinePlus [6]

Questions

Does Victoza® cause heartburn?

It can. The EU classes reflux disease as common and its leaflet names heartburn as the sign, and the US label lists dyspepsia in 4% to 7% of adults against 1% on placebo. [1][2]

Is indigestion the same as heartburn?

No. MedlinePlus describes indigestion as discomfort in the upper belly and heartburn as burning behind the breastbone. [6][7] Victoza®’s documents count them in separate rows. [2][3]

Can I take antacids with Victoza®?

MedlinePlus describes antacids and acid-reducing medicines for heartburn. [6] Ask your pharmacist, who can check them against your other tablets; the Victoza® label already asks for caution with oral medicines. [1]

Why does it matter before an endoscopy or operation?

Victoza® slows stomach emptying, and rare cases of food entering the lungs under anaesthesia or deep sedation have been reported with GLP-1 medicines. [1] Tell the team before the procedure.

I have heart disease. How do I tell heartburn from a heart problem?

You cannot be sure at home. MedlinePlus says burning with chest pressure or squeezing may be a heart attack and needs urgent care. [6] Call emergency services rather than waiting.

I burp a lot since starting Victoza®. Is that listed?

Yes. The Canadian patient information lists burping among common side effects, alongside indigestion and reflux. [3]

Sources

Sources checked on

  1. VICTOZA® (liraglutide) injection Prescribing Information and Medication Guide, Novo Nordisk Revised 10/2025; Medication Guide 05/2025. Sections 5.9, 6.1 (Table 1), 7.1, 12.2, 14.3 and 17.
  2. Victoza: EPAR – Product Information (SmPC and package leaflet), European Medicines Agency SmPC sections 4.4 and 4.8 (Table 1 read from the PDF page image); package leaflet section 4.
  3. VICTOZA® (liraglutide injection) Product Monograph, Novo Nordisk Canada Inc. (Health Canada Drug Product Database) Date of authorization 2025-08-21. Section 8.2 (Tables 1–3 read from the PDF page images); patient medication information.
  4. Noh Y et al. Glucagon-like peptide-1 receptor agonists and risk for gastroesophageal reflux disease in patients with type 2 diabetes: a population-based cohort study. Ann Intern Med 2025 Active-comparator new-user cohort, UK Clinical Practice Research Datalink; PubMed abstract.
  5. Chiang CH et al. Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis. Gastroenterology 2025 Meta-analysis of 55 placebo-controlled randomised trials; PubMed abstract.
  6. Heartburn, MedlinePlus Medical Encyclopedia (U.S. National Library of Medicine)
  7. Indigestion, MedlinePlus Medical Encyclopedia